Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Mi-Hyang | - |
dc.contributor.author | Lee, Ju-Hee | - |
dc.contributor.author | Lee, Chan Joo | - |
dc.contributor.author | Shin, Jeong-Hun | - |
dc.contributor.author | Kang, Si Hyuck | - |
dc.contributor.author | Kwon, Chang Hee | - |
dc.contributor.author | Kim, Dae-Hee | - |
dc.contributor.author | Kim, Woo-hyeun | - |
dc.contributor.author | Kim, Hack Lyoung | - |
dc.contributor.author | Kim, Hyue Mee | - |
dc.contributor.author | Cho, In Jeong | - |
dc.contributor.author | Cho, Iksung | - |
dc.contributor.author | Hwang, Jinseub | - |
dc.contributor.author | Ryu, Soorack | - |
dc.contributor.author | Kang, Chaeyeong | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Chung, Wook-Jin | - |
dc.contributor.author | Ihm, Sang-Hyun | - |
dc.contributor.author | Kim, Kwang Il | - |
dc.contributor.author | Cho, Eun Joo | - |
dc.contributor.author | Sohn, Il-Suk | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Ryu, Sung Kee | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Kang, Seok-Min | - |
dc.contributor.author | Pyun, Wook Bum | - |
dc.contributor.author | Cho, Myeong-Chan | - |
dc.contributor.author | Sung, Ki-Chul | - |
dc.date.accessioned | 2021-07-30T04:45:02Z | - |
dc.date.available | 2021-07-30T04:45:02Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.issn | 1751-7176 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/1236 | - |
dc.description.abstract | The potential cancer risk associated with long-term exposure to angiotensin receptor blockers (ARBs) is still unclear. We assessed the risk of incident cancer among hypertensive patients who were treated with ARBs compared with patients exposed to angiotensin-converting enzyme inhibitors (ACEIs), which are known to have a neutral effect on cancer development. Using the Korean National Health Insurance Service database, we analyzed the data of patients diagnosed with essential hypertension from January 2005 to December 2012 who were aged >= 40 years, initially free of cancer, and were prescribed either ACEI or ARB (n = 293,962). Cox proportional hazard model adjusted for covariates was used to evaluate the risk of incident cancer. During a mean follow-up of 10 years, 24,610 incident cancers were observed. ARB use was associated with a decreased risk of overall cancer compared with ACEI use (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.72-0.80). Similar results were obtained for lung (HR 0.73, 95% CI 0.64-0.82), hepatic (HR 0.56, 95% CI 0.48-0.65), and gastric cancers (HR 0.74, 95% CI 0.66-0.83). Regardless of the subgroup, greater reduction of cancer risk was seen among patients treated with ARB than that among patients treated with ACEIs. Particularly, the decreased risk of cancer among ARB users was more prominent among males and heavy drinkers (interaction P < .005). Dose-response analyses demonstrated a gradual decrease in risk with prolonged ARB therapy than that with ACEI use. In conclusion, ARB use was associated with a decreased risk of overall cancer and several site-specific cancers. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jch.14187 | - |
dc.identifier.scopusid | 2-s2.0-85099909365 | - |
dc.identifier.wosid | 000611181400001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.23, no.4, pp 879 - 887 | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 23 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 879 | - |
dc.citation.endPage | 887 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | angiotensin receptor antagonist | - |
dc.subject.keywordPlus | benazepril | - |
dc.subject.keywordPlus | calcium channel blocking agent | - |
dc.subject.keywordPlus | candesartan | - |
dc.subject.keywordPlus | captopril | - |
dc.subject.keywordPlus | delapril | - |
dc.subject.keywordPlus | dipeptidyl carboxypeptidase inhibitor | - |
dc.subject.keywordPlus | diuretic agent | - |
dc.subject.keywordPlus | enalapril | - |
dc.subject.keywordPlus | eprosartan | - |
dc.subject.keywordPlus | fimasartan | - |
dc.subject.keywordPlus | fosinopril | - |
dc.subject.keywordPlus | imidapril | - |
dc.subject.keywordPlus | irbesartan | - |
dc.subject.keywordPlus | lisinopril | - |
dc.subject.keywordPlus | losartan | - |
dc.subject.keywordPlus | moexipril | - |
dc.subject.keywordPlus | olmesartan | - |
dc.subject.keywordPlus | perindopril | - |
dc.subject.keywordPlus | quinapril | - |
dc.subject.keywordPlus | ramipril | - |
dc.subject.keywordPlus | telmisartan | - |
dc.subject.keywordPlus | temocapril | - |
dc.subject.keywordPlus | valsartan | - |
dc.subject.keywordPlus | zofenopril | - |
dc.subject.keywordPlus | angiotensin receptor antagonist | - |
dc.subject.keywordPlus | dipeptidyl carboxypeptidase inhibitor | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | alcohol consumption | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | bladder cancer | - |
dc.subject.keywordPlus | body mass | - |
dc.subject.keywordPlus | breast cancer | - |
dc.subject.keywordPlus | cancer incidence | - |
dc.subject.keywordPlus | cancer risk | - |
dc.subject.keywordPlus | cohort analysis | - |
dc.subject.keywordPlus | colorectal cancer | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | disease association | - |
dc.subject.keywordPlus | drug exposure | - |
dc.subject.keywordPlus | essential hypertension | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | heavy drinker | - |
dc.subject.keywordPlus | high risk patient | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | ICD-10 | - |
dc.subject.keywordPlus | income | - |
dc.subject.keywordPlus | kidney cancer | - |
dc.subject.keywordPlus | liver cancer | - |
dc.subject.keywordPlus | low risk patient | - |
dc.subject.keywordPlus | lung cancer | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | malignant neoplasm | - |
dc.subject.keywordPlus | obesity | - |
dc.subject.keywordPlus | pancreas cancer | - |
dc.subject.keywordPlus | prescription | - |
dc.subject.keywordPlus | prevalence | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prostate cancer | - |
dc.subject.keywordPlus | sex difference | - |
dc.subject.keywordPlus | smoking | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | stomach cancer | - |
dc.subject.keywordPlus | systolic blood pressur | - |
dc.subject.keywordAuthor | angiotension II type 1 receptor blockers | - |
dc.subject.keywordAuthor | antihypertensive agents | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | neoplasms | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jch.14187 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.